IQVIA Holdings Inc. (NYSE:IQV) Short Interest Update

IQVIA Holdings Inc. (NYSE:IQV) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 3,150,000 shares, a decline of 17.3% from the March 15th total of 3,810,000 shares. Currently, 1.8% of the company’s shares are short sold. Based on an average daily trading volume, of 1,660,000 shares, the short-interest ratio is presently 1.9 days.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. American National Bank & Trust acquired a new position in IQVIA in the first quarter valued at $26,000. Synergy Asset Management LLC acquired a new position in IQVIA during the fourth quarter worth approximately $33,000. ST Germain D J Co. Inc. lifted its stake in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $39,000. Finally, Lee Danner & Bass Inc. acquired a new position in shares of IQVIA in the 4th quarter valued at $44,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 3.2 %

NYSE IQV opened at $143.66 on Friday. IQVIA has a 52 week low of $135.97 and a 52 week high of $252.88. The firm has a 50 day moving average of $176.42 and a two-hundred day moving average of $196.62. The stock has a market capitalization of $25.33 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on IQV shares. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Truist Financial decreased their target price on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a report on Thursday, April 10th. Mizuho cut their price target on shares of IQVIA from $242.00 to $210.00 and set an “outperform” rating for the company in a report on Wednesday, April 9th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $241.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.